ad image

Servier CDMO

1 / 2
Road to 2021 Day 24: France
The Road to 2021

Road to 2021 Day 24: France

Nigel Walker

Nice Insight

PAO-04-22-R221-51Jan 01, 2021
Servier

Servier Acquires Symphogen

Servier

PR-M04-20-NI-006Apr 03, 2020
Revisiting the Global Serialization Landscape
Serialization Update

Revisiting the Global Serialization Landscape

Michael Kinsella

Servier

PAP-Q2-2019-CL-030May 24, 2019
Servier
Expansion

Servier Cuts Ribbon on New Boston Headquarters

Servier

PR-M05-19-NI-037May 13, 2019
Highly Potent API and Sterile Capabilities Key to DCAT Week ‘19 Company Announcements
DCAT '19

Highly Potent API and Sterile Capabilities Key to DCAT Week ‘19 Company Announcements

David Alvaro, Ph.D.

Pharma's Almanac

PAO-M03-19-NI-024Mar 18, 2019
Amgen
Collaboration

Amgen, Cytokinetics and Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure

Amgen

PR-M02-19-NI-052Feb 22, 2019
Risk Minimization with an Integrated Global Network
Global Network

Risk Minimization with an Integrated Global Network

Servier

PAP-Q4-18-CL-005Oct 26, 2018
Preparative Chromatography
Design Logic

Preparative Chromatography

Nice Insight

PAP-Q4-18-NI-002Oct 26, 2018
Accelerating Time to Market with Integrated Preparative Chromatography Support
Chromatography

Accelerating Time to Market with Integrated Preparative Chromatography Support

Christophe Berini

Servier

PAP-Q3-18-CL-010Oct 02, 2018
Shire Exec Selected to Run Servier Pharmaceuticals U.S.
Announcement

Shire Exec Selected to Run Servier Pharmaceuticals U.S.

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-M07-18-NI-015Jul 24, 2018
Reducing Time to Market with Targeted Regulatory Affairs Support
Regulatory

Reducing Time to Market with Targeted Regulatory Affairs Support

Maryse Phan

Servier

PAO-06-18-CL-003Jun 20, 2018
Corporate Social Responsibility as a Driver for Improved Sustainability
Corporate Social Responsibility

Corporate Social Responsibility as a Driver for Improved Sustainability

Allain de Wilde; Loïc Allanos

Servier

PAP-Q2-18-CL-014May 29, 2018
Servier
Endpoint

Phase III Study Evaluating the Efficacy and Safety of Lonsurf in Patients with Metastatic Gastric Cancer Meets Primary Endpoint

Servier

PR-M05-18-NI-040May 10, 2018
Servier
Acquisition

Shire Announces Sale of Oncology Business to Servier for $2.4 Billion

Servier

PR-M04-18-NI-59Apr 16, 2018
Transforming A CDMO Using an Operational Excellence Approach
Operational Excellence

Transforming A CDMO Using an Operational Excellence Approach

Sébastien Mathieu; Laurent Dray

Servier

PAO-M03-18-CL-003Mar 29, 2018
Servier
Innovation

WeHealth by Servier and DEEPLINK MEDICAL sign a partnership to develop a new e-health solution

Servier

PR-M03-18-NI-059Mar 16, 2018
Why Business Continuity Management is Important for CDMOs
Industry

Why Business Continuity Management is Important for CDMOs

Mayeul Cauvin

Servier

PAP-Q1-18-CL-003Mar 12, 2018
Servier Reports Year-On-Year Growth

Servier Reports Year-On-Year Growth

Guy Tiene

Nice Insight

PAO-M02-18-NI-024Feb 27, 2018
Servier
Strategic Partnership

ImmunoQure AG and Servier Enter into Strategic Partnership for the Development of an Interferon-alpha Human Autoantibody

Servier

PR-M02-18-NI-64-4706Feb 14, 2018
Taiho Oncology, Inc.
Symposium

Taiho Oncology and Servier Present LONSURF® (trifluridine and tipiracil) Metastatic Colorectal Cancer (mCRC) Data at ASCO 2018 Gastrointestinal Cancers Symposium

Taiho Oncology, Inc.

PR-M01-18-NI-080Jan 25, 2018
1 / 2